EP2640359A4 - Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie - Google Patents

Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie

Info

Publication number
EP2640359A4
EP2640359A4 EP11841427.5A EP11841427A EP2640359A4 EP 2640359 A4 EP2640359 A4 EP 2640359A4 EP 11841427 A EP11841427 A EP 11841427A EP 2640359 A4 EP2640359 A4 EP 2640359A4
Authority
EP
European Patent Office
Prior art keywords
cancer therapy
novel compositions
hypertension agents
hypertension
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11841427.5A
Other languages
English (en)
French (fr)
Other versions
EP2640359A2 (de
Inventor
Rakesh Kumar Jain
Yves Boucher
Vikash Pal Singh Chauhan
Benjamin Diop-Frimpong
Stephen Krane
Alan L Crane
Robert Samuel Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Original Assignee
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, XTUIT PHARMACEUTICALS Inc filed Critical General Hospital Corp
Publication of EP2640359A2 publication Critical patent/EP2640359A2/de
Publication of EP2640359A4 publication Critical patent/EP2640359A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
EP11841427.5A 2010-11-18 2011-11-18 Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie Withdrawn EP2640359A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41519210P 2010-11-18 2010-11-18
US201161438240P 2011-01-31 2011-01-31
PCT/US2011/061510 WO2012068531A2 (en) 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy

Publications (2)

Publication Number Publication Date
EP2640359A2 EP2640359A2 (de) 2013-09-25
EP2640359A4 true EP2640359A4 (de) 2015-11-04

Family

ID=46084685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11841427.5A Withdrawn EP2640359A4 (de) 2010-11-18 2011-11-18 Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie

Country Status (7)

Country Link
EP (1) EP2640359A4 (de)
JP (2) JP2014505666A (de)
CN (1) CN103561726A (de)
AU (1) AU2011329638C1 (de)
CA (1) CA2817250A1 (de)
RU (2) RU2018102375A (de)
WO (1) WO2012068531A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8710013B2 (en) 2008-04-18 2014-04-29 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
BRPI0920121A2 (pt) 2008-10-15 2019-09-24 Angiochem Inc conjugados de etoposida e doxorubicina para liberação de fármaco
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
EP2421562B1 (de) 2009-04-20 2019-03-13 Angiochem Inc. Behandlung von ovarialkarzinom mit einem an ein angiopep-2-analogon konjugierten antitumorwirkstoff
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
EP3939572B1 (de) 2012-04-12 2024-03-27 Yale University Trägersubstanz zur kontrollierten abgabe verschiedener pharmazeutischer wirkstoffe
AU2013259772A1 (en) * 2012-05-07 2014-12-04 Massachusetts Institute Of Technology Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
US9717731B2 (en) * 2012-11-02 2017-08-01 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment
WO2014134621A2 (en) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
JP6702722B2 (ja) * 2013-04-10 2020-06-03 公立大学法人奈良県立医科大学 肝細胞がんの予防及び／又は治療剤
CN110302162A (zh) * 2013-11-01 2019-10-08 耶鲁大学 用于免疫疗法的模块化粒子
AU2014344789B2 (en) * 2013-11-01 2019-10-03 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
KR20180021684A (ko) * 2015-04-25 2018-03-05 더 제너럴 하스피털 코포레이션 암 치료용 항-기피주성제와 면역요법제 조합 요법 및 조성물
US10980892B2 (en) 2015-06-15 2021-04-20 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN105326812A (zh) * 2015-10-28 2016-02-17 南昌大学 一种索拉菲尼固体脂质纳米粒及其制备方法
EP3389720A1 (de) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetalpolymere, konjugate, partikel und verwendungen davon
WO2018038253A1 (ja) * 2016-08-26 2018-03-01 哲治 奥野 微小ナノ化薬剤およびその利用
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
CN108358995B (zh) * 2017-01-25 2021-07-06 四川大学 CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用
RU2724398C1 (ru) * 2019-09-03 2020-06-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения степени агрессивности течения рака легкого.
BR112022009955A2 (pt) * 2019-12-13 2022-08-09 Massachusetts Inst Technology Barreiras de tecido sintético e seus usos
EP3842099A1 (de) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Verwendung von losartan zur behandlung von fibrotischen erkrankungen, insbesondere epidermolysis bullosa
CN114917345A (zh) * 2021-04-07 2022-08-19 北京蛋白质组研究中心 靶向soat1蛋白的化合物在制备预防和/或治疗肝癌药物中的应用
CN115317627B (zh) * 2022-08-26 2023-10-24 江西中医药大学 Abt-510肽在制备肿瘤显像剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
DE10144980B4 (de) 2001-09-12 2004-06-03 Webasto Vehicle Systems International Gmbh Führungsvorrichtung für einen Deckel eines zu öffnenden Fahrzeugdaches
JP2007533745A (ja) * 2004-04-20 2007-11-22 アールエヌディー・ファーマシューティカルズ 脂溶性のシリコン置換シクロオキシゲナーゼ−２選択的非ステロイド性抗炎症薬及び誘導体の医薬組成物及び使用方法
US20080299205A1 (en) 2004-07-19 2008-12-04 Mayer Lawrence D Particulate Constructs For Release of Active Agents
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
JPWO2006077901A1 (ja) 2005-01-20 2008-06-19 塩野義製薬株式会社 Ｃｔｇｆ発現阻害剤
CA2930677A1 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
MX2007009960A (es) * 2005-02-18 2008-03-11 Abraxis Bioscience Inc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
EP1993611A4 (de) 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc Rnai-modulation von tgf-beta und ihre therapeutische verwendung
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
WO2009105624A2 (en) * 2008-02-21 2009-08-27 Massachusetts Institute Of Technology Simultaneous delivery of receptors and/or co-receptors for growth factor stability and activity
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
SI2285350T1 (en) 2008-06-16 2018-03-30 Pfizer Inc. Methods for the preparation of diblock copolymers functionalized with targeting agent for use in the manufacture of therapeutic nanoparticles
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
ES2462090T5 (es) 2008-06-16 2017-07-12 Pfizer Inc. Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
ES2776126T3 (es) 2008-12-15 2020-07-29 Pfizer Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos
DE102009002623A1 (de) 2009-04-24 2010-11-04 BSH Bosch und Siemens Hausgeräte GmbH Programmwähler für ein Hausgerät, insbesondere für eine Waschmaschine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
B. DIOP-FRIMPONG ET AL: "Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 7, 31 January 2011 (2011-01-31), pages 2909 - 2914, XP055176833, ISSN: 0027-8424, DOI: 10.1073/pnas.1018892108 *
JAIN RAKESH K ET AL: "Delivering nanomedicine to solid tumors.", NATURE REVIEWS. CLINICAL ONCOLOGY NOV 2010, vol. 7, no. 11, 14 September 2010 (2010-09-14), pages 653 - 664, XP002744524, ISSN: 1759-4782 *
NOGUCHI RYUICHI ET AL: "Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities", ONCOLOGY REPORTS, vol. 22, no. 2, August 2009 (2009-08-01), pages 355 - 360, XP002744523, ISSN: 1021-335X *
RHODES DANIEL R ET AL: "AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 106, no. 25, 23 June 2009 (2009-06-23), pages 10284 - 10289, XP002592235, ISSN: 0027-8424, [retrieved on 20090601], DOI: 10.1073/PNAS.0900351106 *
See also references of WO2012068531A2 *

Also Published As

Publication number Publication date
RU2013127625A (ru) 2014-12-27
RU2018102375A (ru) 2019-02-21
JP2014505666A (ja) 2014-03-06
EP2640359A2 (de) 2013-09-25
JP2017101056A (ja) 2017-06-08
CN103561726A (zh) 2014-02-05
WO2012068531A3 (en) 2013-11-28
AU2011329638B2 (en) 2016-10-13
AU2011329638C1 (en) 2017-04-27
CA2817250A1 (en) 2012-05-24
AU2011329638A1 (en) 2013-05-30
WO2012068531A2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
EP2640359A4 (de) Neue zusammensetzungen und verwendungen blutdrucksenkender mittel zur krebstherapie
HK1211832A1 (zh) 用於癌症療法的抗高血壓藥物的新穎配方及用法
ZA201300567B (en) Methods and compositions for liver cancer therapy
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
EP2603202A4 (de) Zusammensetzungen und verfahren zur behandlung von tauopathien
SG10201508495VA (en) Combination treatment of cancer
IL222291A0 (en) Compositions and methods of synthesis of pyridinoylpiperidine
EP2688594A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
IL251083B (en) Compounds and preparations for the treatment of cancer
EP2526118A4 (de) Zusammensetzungen und verfahren zur behandlung von eierstockkrebs
EP2558599A4 (de) Verfahren zur bewertung des ansprechens auf eine krebstherapie
EP2558085A4 (de) Zusammensetzungen und verfahren zur prävention und behandlung von krebs
PL2605764T3 (pl) Kompozycje do leczenia nowotworu
ZA201302952B (en) Fungicidal compositions and methods of use
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
EP2635273A4 (de) Isoflavonoidzusammensetzungen und verfahren zur krebsbehandlung
WO2012003421A9 (en) Combinational compositions and methods for treatment of cancer
EP2547368A4 (de) Verfahren und zusammensetzungen zur krebsbehandlung
EP2558113A4 (de) Therapeutische serca2-zusammensetzungen und verfahren zu ihrer verwendung
EP2637501A4 (de) Fungizide zusammensetzungen und verwendungsverfahren dafür
GB201019938D0 (en) Determination of therapeutic agents
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

R17D Deferred search report published (corrected)

Effective date: 20131128

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189801

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101ALI20150924BHEP

Ipc: A61K 39/395 20060101ALI20150924BHEP

Ipc: A61K 45/06 20060101AFI20150924BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20151002

17Q First examination report despatched

Effective date: 20170309

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20181211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190424

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1189801

Country of ref document: HK